Moderna Set to Replace Warner Bros. Discovery on Nasdaq 100
Moderna will join the Nasdaq 100 index, displacing Warner Bros. Discovery in a move reflecting shifting market valuations.
Moderna is set to replace Warner Bros. Discovery on the Nasdaq 100 index, marking a significant reshuffle among the benchmark's component stocks. The change reflects ongoing shifts in market capitalization and investor weighting that periodically prompt index administrators to reconfigure their rosters.
The Nasdaq 100 tracks the 100 largest non-financial companies listed on the Nasdaq stock exchange by market capitalization. Periodic reviews allow the index to remain current with market dynamics, removing companies that no longer meet eligibility thresholds and adding those that have risen in relative standing.
Read more National Bank Holdings Books $46.8M in Loan Charge-Offs, Eyes $40.1M Buyback →
Moderna, the biotechnology company best known for its mRNA-based COVID-19 vaccine, has experienced dramatic valuation swings since its pandemic-era surge. Its inclusion signals that the company retains sufficient market weight to warrant a place among the exchange's elite tier of listed firms.
Warner Bros. Discovery, the media and entertainment conglomerate formed through the 2022 merger of WarnerMedia and Discovery, has faced sustained pressure on its share price amid a challenging environment for legacy media companies navigating cord-cutting and streaming competition.
Index reconstitutions of this kind can trigger notable trading activity, as funds and exchange-traded products that track the Nasdaq 100 are required to adjust their holdings to mirror the updated composition. Continue reading at All News.
